[{"from": "human", "value": "Please give me some details about this molecule. [C][C][=Branch2][Branch1][=Branch2][=C][C][C@@H1][C@@][Branch1][Ring2][O][Ring1][Ring1][Branch1][C][C][C@H1][C@@H1][Branch2][Ring2][=Branch1][C@@H1][Branch1][#Branch2][C][C][C@][Ring1][=Branch1][C][O][Ring1][Ring1][O][C][=Branch1][C][=O][/C][=C][/C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][C][N][Branch1][C][C][C][O][C][C]"}, {"from": "gpt", "value": "The molecule is a fumagillin analogue and inhibitor of methionine aminopeptidase 2 (METAP2), with potential antiangiogenic and anti-obesity activity. As an irreversible inhibitor, beloranib blocks METAP2's functions, which include both protecting eukaryotic initiation factor 2 from inhibitory phosphorylation during translation, and by removing the amino-terminal methionine residue from nascent protein permitting the conversion of an inactive or non-functional protein to an active one. As a result, this agent prevents endothelial cell growth and inhibits tumor angiogenesis. In addition, METAP2 inhibition also down-regulates ERK1/2 signaling pathway, which is usually overactive in the fat tissues of obese people. Therefore, at a much lower dose, beloranib can induce liver fat utilization and reduce cholesterol and fatty acid synthesis. METAP2, a member of the dimetallohydrolase family, plays an important role during angiogenesis and is over-expressed in various cancers."}]